KDventures raised SEK 23.9 million via directed share issue
The proceeds will finance the acquisition of Rosetta Capital IV's shares in KDev Investments AB, announced on 17 June 2026.
See the latest news and media coverage for KDventures. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science investment company
kd-ventures.comLast updated
In short: KDventures rebranded from Karolinska Development, managed a significant write-down for Umecrine Cognition, and raised SEK 115.2 million via equity.
The proceeds will finance the acquisition of Rosetta Capital IV's shares in KDev Investments AB, announced on 17 June 2026.
The write-down reduces book value by 65.5%, or SEK 390.1 million, with no cash flow impact.
Shareholders approved financial statements, re-elected directors, and authorized share transfers and new issues.
Shareholders can participate in person, by postal vote, or by proxy. The agenda includes election of directors and authorization proposals.
KDventures’ portfolio company Umecrine Cognition has reported new data showing that more than half of primary biliary cholangitis patients suffer severe central fatigue and cognitive...
STOCKHOLM, Sweden, April 9, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a collaboration with Touchlight...
The shareholders in KDventures AB (publ), org. no. 556707-5048, (“KDventures” or “the Company”), are invited to the annual general meeting on Tuesday, May 12, 2026 at 15.00 at Nanna Svartz väg 2...
STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering...
Track KDventures and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to KDventures and other trending companies.